Staff

Director

marc-wilkins
Professor Marc Wilkins is the Director of the Initiative. Professor Wilkins holds the chair of Systems Biology in the School of Biotechnology and Biomolecular Sciences. His research interests involve the proteomics of protein-protein interactions and systems biology. Specifically, Professor Wilkins' research focuses on the dynamics of protein-protein interaction networks, and the role that gene expression and protein post-translational modifications play in the control of protein interactions and thus delivery of cellular function in yeast and human cells. For more information about Prof Wilkins' research, please …link…

Affiliated Staff

rchard-edwards
Dr Richard Edwards a Senior Lecturer in Bioinformatics in the School of Biotechnology and Biomolecular Sciences. His research focuses on the evolutionary and network dynamics of protein-protein interactions mediated by short linear motifs (SLiMs). Research in the group combines sequence analysis tools with structural data and protein-protein interaction networks to predict novel SLiMs and understand their role in cellular processes and disease. For more information about Dr Edwards' research, please click here.
gene-hartsmith
Dr Gene Hart-Smith  is an ARC DECRA Fellow working within the SBI. He completed a PhD in the field of polymer chemistry - utilising mass spectrometry as a primary tool - and has since applied these analytical techniques to the study of biological systems.  His research at the SBI is centred around the examination of protein-protein interaction networks. He is particularly interested in the impacts of post-translational methylation on the dynamics of these networks, and is currently developing and applying mass spectrometric methods towards the investigation of these phenomena in Saccharomyces cerevisiae.

Postdoctoral Research Fellows

susan-corely
Dr Susan Corley  started working as a Bioinformatics Research Scientist at the SBI in 2012. She graduated with a BSc (Hons), majors in Chemistry and Pharmacology from the University of Sydney in 2005 and then went on to complete a PhD at the John Curtin School of Medical Research (ANU). Her research focused on the neural protein, Shadoo, and more generally explored protein-RNA interactions. This research was undertaken using computational and biophysical approaches. Now Susan predominantly works on transcriptomic research of mammalian tissue. She is very experienced in RNA-seq techniques as well as in the analysis of microarray, CHiPseq and high throughput qPCR. Her work has helped collaborators gain a better understanding of the genes and pathways involved in human health and disease. Susan’s projects cover a wide breadth and have included expression analysis relating to Crohn’s disease, Schizophrenia, Williams-Beurens syndrome, Kerataconus, Immunity related conditions and Cancer cachexia.
nandan-deshpan
Dr Nandan Deshpande is a postdoctoral fellow working at the SBI. He graduated with an MS in Biomedical Engineering from the University of Texas (Southwestern Medical Center) in Dallas, USA. As a bioinformatics scientist at the Institute of Bioinformatics (Bangalore, India), he was involved in many projects based on genomic data integration, visualization and analysis. His PhD, titled "'SYSTEM'atic integration of glycosylation related processes: A bioinformatic initiative", was based on the analysis of glycosylation related pathways. His current interests at SBI include the assembly and annotation of genomes sequenced using next generation sequencers.
adam-palmer
Dr Adam Palmer is a NHMRC Early Career Fellow in the Laboratory of Systems Pharmacology at Harvard Medical School and the Systems Biology Initiative at UNSW. He received his B.Sc (Honours) from The University of Adelaide, Australia, where he completed majors in Biochemistry, Chemistry, and Physics. He completed his Ph.D in Systems Biology at Harvard University, USA, in the laboratory of Roy Kishony, where he investigated the effects of genetic interactions and drug interactions on the evolution and mechanisms of antibiotic resistance. Adam is presently in the laboratory of Peter Sorger studying combination cancer therapies, in particular how therapeutic efficacy depends on within-tumor and between-patient heterogeneity. (CJ Martin Fellow) – current post-doc.
ignatius-pang
Dr Ignatius Pang completed his PhD in 2010 on the topic "The Dynamics of Protein Interaction Networks." In his thesis, he explored different mechanisms that govern the dynamics of protein-protein interactions - such as how changes in domain-domain interactions, post-translational modifications, and protein abundance can dynamically switch on/off protein-protein interactions. He also performed a large-scale screen of arginine and lysine methylation in the yeast proteome, and found that there are more methylated proteins than previously thought. Before starting his current role, Ignatius worked in Deloitte as a part of their data analytics team. His current research projects include protein methylation, as well as understanding how human genetic variations can influence the dynamics of protein interaction networks, thereby providing insights into the cause of human diseases such as cancer.
Dr Xabier Vázquez-Campos joined SBI as postdoctoral fellow in 2017. He received his Licenciate degree in Biology from the University of Vigo (Spain) in 2007 and MSc in Microbiology from the Autonomous University of Madrid (Spain) in 2008. Xabier completed his PhD at UNSW in 2015 with a thesis entitled "Geomicrobiological aspects of the (bio)leaching of weathered low-grade uranium ore", where he explored diverse aspects of the microbes inhabiting the extremely acidic environments at Ranger Uranium Mine. He continued to his first postdoctoral position with a project involving the metagenomic analysis of groundwater samples from a radioactive legacy site.
Yu-Wen Lai completed her PhD in 2016 at the University of Sydney with Professor Dee Carter. Her thesis, 'Transcriptomic analysis of synergy between antifungal drugs and iron chelators for alternative antifungal therapies', aimed to understand the mechanisms through which the drug amphotericin B and natural glycoprotein lactoferrin enhanced the killing of the fungal pathogen Cryptococcus. The holistic analysis of biological pathways and processes perturbed in amphotericin B and lactoferrin treatment, compared to amphotericin treatment alone, were further investigated to find potential anti-cryptococcal and broad spectrum antifungal targets.